<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01020253</url>
  </required_header>
  <id_info>
    <org_study_id>YCU07-122</org_study_id>
    <nct_id>NCT01020253</nct_id>
  </id_info>
  <brief_title>The Effectiveness of Two Osteoporosis Drugs on Prosthetic Bone Mineral Density (BMD) Loss After Total Hip Arthroplasty(THA)</brief_title>
  <acronym>ETOD</acronym>
  <official_title>A Comparison of Alendronate vs. Alfacalcidol Medication for the Preservation of Bone Mineral Density Around the Femoral Implant and in the Lumbar Spine After a Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yokohama City University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yokohama City University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether alendronate and alfacalcidol are effective
      on prosthetic or lumbar spine BMD after total hip arthroplasty.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DEXA QDR 2000, Hologic Co.</measure>
    <time_frame>1, 12, 24 and 48 weeks after operation</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Bone Density</condition>
  <condition>Arthroplasty, Replacement, Hip</condition>
  <arm_group>
    <arm_group_label>Alendronate medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alfacalcidol medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-medication</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alendronate, alfacalcidol</intervention_name>
    <description>Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1Î¼g per day, Tablet, Duration is 48 weeks.</description>
    <arm_group_label>Alendronate medication</arm_group_label>
    <arm_group_label>Alfacalcidol medication</arm_group_label>
    <arm_group_label>Non-medication</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  osteoarthritis of the hip

          -  patients after total hip arthroplasty

        Exclusion Criteria:

          -  diseases related to bone metabolism

          -  patients taking drugs which affect bone metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>44 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of orthopaedic surgery, Yokohama City University</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>December 2, 2009</last_update_submitted>
  <last_update_submitted_qc>December 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Naoyuki Iwamoto</name_title>
    <organization>Yokohama City University</organization>
  </responsible_party>
  <keyword>bisphosphonate, vitamin D3</keyword>
  <keyword>Total Hip arthroplasty</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfacalcidol</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

